Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced
today that data from an independent study, which showed that
BarreGEN® performed effectively as a biomarker tool for predicting
risk of developing more advanced stages of disease prior to visible
appearance of advanced histology, will be presented at the annual
Digestive Disease Week® (“DDW”). The meeting will be held in San
Diego, CA on May 18-21, 2019, and is the largest international
gathering of physicians, researchers and academics in the fields of
gastroenterology, hepatology, endoscopy and gastrointestinal
surgery.
Poster Details Below
Presentation Title: Mutational Load Predicts Risk of Progression
In Barrett's Esophagus Patients With Indefinite For Dysplasia
(abstract #3101561)Session Title: Barrett's Esophagus: Diagnosis,
Management and Surveillance Session Date: May 18, 2019 Presentation
Time: 12:00-2:00pm PT
The study was conducted at the Division of
Gastroenterology, Zucker School of Medicine at Hofstra/Northwell,
Long Island Jewish Medical Center, Northwell Health System, New
Hyde Park, New York and the authors were Trindade AJ, McKinley MJ,
and Alshelleh M., et. al. The study is available on the BMJ Open
Gastroenterology website.
During DDW, Interpace will also be hosting a Key
Opinion Leader (“KOL”) program, which will focus on our PancraGEN®
product for pancreatic cancer and an inaugural Fellowship program
led by Dr. Tamas Gonda, a renowned Gastroenterologist at Columbia
University, bringing together fellows from several New York City
area academic healthcare centers to provide them background
information on molecular testing for pancreatic cancer.
Jack Stover, President and CEO of Interpace,
stated, “We are pleased to have the opportunity to present this
most recent data on BarreGEN® at a high-profile event such as DDW,
allowing us to educate the medical community on this molecular
diagnostic test and further enhancing the understanding of
molecular medicine in pancreatic cancer among physician leaders and
fellows alike.”
About DDW
Digestive Disease Week® (DDW) is the largest
international gathering of physicians, researchers and academics in
the fields of gastroenterology, hepatology, endoscopy and
gastrointestinal surgery. Jointly sponsored by the American
Association for the Study of Liver Diseases (AASLD), the American
Gastroenterological Association (AGA) Institute, the American
Society for Gastrointestinal Endoscopy (ASGE) and the Society for
Surgery of the Alimentary Tract (SSAT), DDW takes place May 18-21,
2019, at the San Diego Convention Center. The meeting showcases
more than 5,000 abstracts and hundreds of lectures on the latest
advances in GI research, medicine and technology. More information
can be found at https://ddw.org/home.
About BarreGEN®
BarreGEN® is a molecular based assay that
measures mutational load from specimens obtained from the esophagus
that are suspicious for Barrett’s Esophagus, one of the leading
causes of Esophageal Cancer. Millions of Americans with Barrett’s
Esophagus undergo expensive, unnecessary procedures and therapies
in efforts to identify and prevent cancer at its earliest stages.
Common pathology diagnosis cannot identify which patients with
non-dysplastic BE, IND or LGD will progress to cancer and which
patients will not progress to esophageal carcinoma. Per the summary
of a study published in 2015 in the journal Gastroenterology, “The
Presence of Genetic Mutations at Key Loci Predicts Progression to
Esophageal Carcinoma in Barrett’s Esophagus.”
About PancraGEN®
PancraGEN® is a molecular, pancreatic cancer
risk classifier for cysts, solid lesions, and biliary strictures
that, by using a small sample of pancreatic cyst fluid, can aid in
pancreatic cancer risk assessment. PancraGEN® is 90% accurate
according to clinical studies, enabling effective risk
stratification of patients. Pancreatic cancer is often difficult to
diagnose in early stages and typically spreads rapidly with signs
and symptoms appearing when the cancer is significantly advanced.
Because of this, and that complete surgical removal of the pancreas
is not possible, pancreatic cancer is one of the leading causes of
cancer deaths.
About Interpace Diagnostics Group
Interpace is a fully integrated commercial and
bioinformatics company that provides clinically useful molecular
diagnostic tests and pathology services for evaluating risk of
cancer by leveraging the latest technology in personalized medicine
for improved patient diagnosis and management.
Interpace’s mission is to provide personalized medicine
through molecular diagnostics, innovation and data to advance
patient care based on rigorous science. The Company currently has
four commercialized molecular tests and one test in a clinical
evaluation process (CEP); PancraGEN® for the diagnosis and
prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT®
for the diagnosis of thyroid cancer from thyroid nodules utilizing
a next generation sequencing assay; ThyraMIR® for the diagnosis of
thyroid cancer from thyroid nodules utilizing a proprietary gene
expression assay; and RespriDx® that differentiates lung cancer of
primary vs. metastatic origin. BarreGEN® for Barrett's Esophagus,
is currently being “soft launched” with key opinion leaders as we
continue to gather data on this assay that will assist us in
seeking favorable reimbursement as well as important clinical
information. Barrett's Esophagus is a rapidly growing diagnosis
that affects over three million people in the US and over time can
progress to esophageal cancer. The Company’s data base includes
data from over 50,000 patients who have been tested using the
Company’s current products, including over 25,000 molecular tests
for thyroid nodules. Interpace has been designated by the 2018
edition of CIO Applications as one of the top 10 companies for
providing bioinformatics solutions. Interpace’s mission is to
provide personalized medicine through molecular diagnostics,
innovation and data to advance patient care based on rigorous
science. For more information, please visit Interpace’s website at
www.interpacediagnostics.com.
Forward Looking Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, relating to the
Company's future financial and operating performance. The Company
has attempted to identify forward looking statements by terminology
including "believes," "estimates," "anticipates," "expects,"
"plans," "projects," "intends," "potential," "may," "could,"
"might," "will," "should," "approximately" or other words that
convey uncertainty of future events or outcomes to identify these
forward-looking statements. These statements are based on current
expectations, assumptions and uncertainties involving judgments
about, among other things, future economic, competitive and market
conditions and future business decisions, all of which are
difficult or impossible to predict accurately and many of which are
beyond the Company's control. These statements also involve known
and unknown risks, uncertainties and other factors that may cause
the Company's actual results to be materially different from those
expressed or implied by any forward-looking statement. Known and
unknown risks, uncertainties and other factors include, but are not
limited to, the fact that success in clinical studies may not be
replicated in later studies or demonstrate the clinical utility of
the test, the market's acceptance of its molecular diagnostic tests
and the Company’s ability to retain and secure reimbursement among
other things. Additionally, all forward-looking statements are
subject to the “Risk Factors” detailed from time to time in the
Company's most recent Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q. Because of these and other risks,
uncertainties and assumptions, undue reliance should not be placed
on these forward-looking statements. In addition, these statements
speak only as of the date of this press release and, except as may
be required by law, the Company undertakes no obligation to revise
or update publicly any forward-looking statements for any
reason.Because of these and other risks, uncertainties and
assumptions, undue reliance should not be placed on these
forward-looking statements. In addition, these statements speak
only as of the date of this press release and, except as may be
required by law, the Company undertakes no obligation to revise or
update publicly any forward-looking statements for any reason.
CONTACTS:Investor Relations - Edison
GroupJoseph Green(646) 653-7030jgreen@edisongroup.com
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Apr 2023 to Apr 2024